Efficacy of interleukin-1 blockade with anakinra in the management of post-COVID-19 steroid-dependent multisystem inflammatory syndrome: a case report

Scand J Rheumatol. 2023 Mar;52(2):230-232. doi: 10.1080/03009742.2022.2140485. Epub 2022 Nov 22.

Authors

E Rinaldi¹, A Tomelleri^{1

2}, C Campochiaro^{1

2}, L Dagna^{1

2}

Affiliations

¹ Vita-Salute San Raffaele University, Milan, Italy.
² Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy.

PMID: 36412129
DOI: 10.1080/03009742.2022.2140485

No abstract available

Publication types

Case Reports

MeSH terms

Antirheumatic Agents* / therapeutic use
COVID-19*
Humans
Interleukin 1 Receptor Antagonist Protein / therapeutic use
Interleukin-1
Steroids

Substances

Interleukin 1 Receptor Antagonist Protein
Interleukin-1
Antirheumatic Agents
Steroids